Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paravertebral Block in Thoracic Outlet Syndrome
NCT05544721Phase 4Enrolling by invitation
- Sponsor
- Mayo Clinic
- Start
- Oct 2022
- Primary completion
- Aug 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of ropivacaine in thoracic outlet syndrome (TOS) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Change in pain level at 14 days. Started Oct 2022; status: enrolling by invitation.
02
Drugs
ropivacaine
03
Conditions
thoracic outlet syndrome (TOS)
Beyond the preview
Go deeper on NCT05544721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05544721.